A First – Smartphone Diagnostic Device Replicates Quality of Lab Blood Test
|
By LabMedica International staff writers Posted on 09 Feb 2015 |

Image: Newly developed diagnostic smartphone accessory device successfully performed point-of-care HIV and syphilis tests in Rwanda from finger-prick whole blood in 15 minutes, operated by healthcare workers easily trained via a software app (Photo courtesy of Samiksha Nayak for Columbia Engineering).
Researchers have developed a hand-held smartphone accessory that can perform a low-cost, point-of-care (POC), lab-quality test that simultaneously detects 3 infectious disease markers from a single finger-prick blood sample in only 15 minutes. The device can also be further developed to test for additional biomarkers.
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
Latest Immunology News
- Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
- Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
- Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
- New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
- Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read more
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
Lassa fever remains a persistent public health threat in West Africa, causing an estimated 100,000–300,000 infections annually and high case fatality rates among hospitalized patients. Clinical management... Read more
Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
Hepatitis E virus is a leading cause of acute viral hepatitis globally, yet infections often go unnoticed in healthy individuals. For patients with preexisting liver damage, however, infection can trigger... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channel




.jpg)


